Screener
Rhythm Pharmaceuticals, Inc. RYTM Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | 2025 |
|---|---|---|
| Total other income (expense), net | (2,733) | (2,414) |
| Loss before income taxes | (55,094) | (49,418) |
| Provision for income taxes | 545 | 80 |
| Net loss | $(55,639) | $(49,498) |
| Accrued dividends on convertible preferred stock | (1,104) | (1,322) |
| Net loss attributable to common stockholders | $(56,743) | $(50,820) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.83) | $(0.81) |
| Weighted-average common shares outstanding, basic and diluted | 67,974,193 | 63,059,165 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s net income?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported net income of -$55.64M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s net income changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s net income decreased by 12.4% year-over-year, from -$49.5M to -$55.64M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s net income?
- Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s net income has grown at a 29.6% compound annual growth rate (CAGR), from -$69.61M to -$196.54M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude